...Hi, everyone. My name is Matt Phipps. I'm a biotech analyst here at William Blair, covering Incyte. Happy to have them here at our 43rd Annual Growth Stock Conference. Obviously, first and foremost, please visit williamblair.com for any and all disclosures. But we have Herve Hoppenot, the CEO and Chairman of Incyte, that will give us a presentation today. I think it's clearly an important time for the company as Jakafi continues to dominate, but now it's definitely always a question of what's next. Opzelura is launching well, but I hope to see that continue to grow. So we'll hear about that and some more things in the pipeline today. So Herve, I'll turn it over to you. Herve Hoppenot ...